Clinical Trial Update: A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat [Phase 3]

View source ↗

Summary

Pfizer-sponsored Phase 3 trial comparing valdecoxib 20 mg twice daily, valdecoxib 40 mg daily, and placebo for pharyngitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pharyngitis

Drugs mentioned

• Valdecoxib (valdecoxib)

Snippet

Sponsor: Pfizer | Conditions: Pharyngitis | Phase 3 | Status: COMPLETED